In the phase II PHERGain study, 95.4% of patients who followed a chemotherapy de-escalation strategy using PHERGain’s adaptive design remained cancer-free after three years of follow-up, and around 30% of patients responded to a fully chemotherapy-free regimen as part of their treatment for HER2- positive breast cancer.
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
